Dr. Paul Curtin along with his colleagues from Icahn School of Medicine at Mount Sinai in New York City have discovered that autism spectrum disorder (ASD) can be predicted in advance, by looking at zinc and copper metabolic cycles in a baby’s teeth. This discovery could lead to the development of novel diagnostic tools with a 90% accuracy level.
Roche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.